Nghiên cứu lâm sàng | boehringerone.com

metabolic

Experts’ perspectives on the EMPA-REG OUTCOME

Experts’ perspectives on the EMPA-REG OUTCOME (Kramer CK and Zinman B) Eur Heart J 37(42):3201-3202, 2016.
In light of the results of the EMPA-REG OUTCOME study which demonstrate for the first time a robust beneficial impact of an antidiabetic medication on CV outcomes, the use of SGLT-2 inhibitors preferentially for the patient population with T2DM and established CV disease might represent a new treatment paradigm to prevent CV disease in that setting.

Three different specialty perspectives on EMPA-REG OUTCOME

Three different specialty perspectives on EMPA-REG OUTCOME
The endocrinologist's point of view (Perreault L. Am J Cardiol 120(S1):S48-S52, 2017.)
doi: 10.1016/j.amjcard.2017.05.010

Three different specialty perspectives on EMPA-REG OUTCOME The cardiologist's point of view (Pham SV, Chilton RJ. Am J Cardiol 120(S1):S53-S58, 2017)

Three different specialty perspectives on EMPA-REG OUTCOME
The cardiologist's point of view (Pham SV, Chilton RJ. Am J Cardiol 120(S1):S53-S58, 2017)
doi: 10.1016/j.amjcard.2017.05.011

Three different specialty perspectives on EMPA-REG OUTCOME The nephrologist's point of view (Wanner C. Am J Cardiol 120(S1):S59-S67, 2017.)

Three different specialty perspectives on EMPA-REG OUTCOME
The nephrologist's point of view (Wanner C. Am J Cardiol 120(S1):S59-S67, 2017.)
doi: 10.1016/j.amjcard.2017.05.012

Tubuloglomerular feedback and renal protection with empagliflozin

Tubuloglomerular feedback and renal protection with empagliflozin

Role of the cardiologist in diabetes management

Role of the cardiologist in diabetes management

Reductions in CV outcomes and CV mortality with empagliflozin in Asian patients

Reductions in CV outcomes and CV mortality with empagliflozin in Asian patients

cardiovascular

Presentation slide: RE-DUAL PCI –antithrombotic therapy in AF patients who have undergone stent PCI

Presentation slide: RE-DUAL PCI –antithrombotic therapy in AF patients who have undergone stent PCI

NEJM Quick Take video summary of The Recircuit Trial

NEJM Quick Take video summary of The Recircuit Trial
Dabigatran was associated with fewer bleeding complications compared to uninterrupted warfarin

Are all NOACs equally safe in the Real World?

Are all NOACs equally safe in the Real World?

The US FDA Medicare study on the use of Dabigatran and Rivaroxaban in elderly patients with NVAF

The US FDA Medicare study on the use of Dabigatran and Rivaroxaban in elderly patients with NVAF

Re-ly asia Analysis and real-world evidences from Asia

Re-ly asia Analysis and real-world evidences from Asia

RE-LY low dose slides

RE-LY low dose slides

Nielsen RWE slide

Nielsen RWE slide

Uninterrupted anticoagulation in catheter ablation: insights from RE‐CIRCUIT Clinical Paper

Uninterrupted anticoagulation in catheter ablation: insights from RE‐CIRCUIT Clinical Paper

RE-DUAL PCI trial article

RE-DUAL PCI trial article

Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation

Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation